Professor
CTSU, Nuffield Department of Population Health, University of Oxford
Consultant Vascular Surgeon
Gloucestershire Royal Hospital
Oxford, United Kingdom
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN
Presenter
SESSION 83: MORE HOT CAROTID AND SUBCLAVIAN TOPICS: UPDATES ON KEY CAROTID RCTS
Presenter
SESSION 93: BEST ANTIPLATELET REGIMENS UPDATE ON RARE VASCULAR DISEASES; NEW DEVELOPMENTS IN ANTIPLATELET AND ANTICOAGULATION REGIMENS AND MEDICAL AND DRUG TREATMENTS
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN
The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels, Elevated Lp(a) And Inflammation: What Are The Best Medical Strategies To Decrease These Parameters: Statins, Adjunctive LDL-C Lowering Drugs Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen, Etc.) And Anti-Inflammatories: How They Should Be Administered
7:16 AM - 7:21 AM
Presenter
SESSION 83: MORE HOT CAROTID AND SUBCLAVIAN TOPICS: UPDATES ON KEY CAROTID RCTS
Update On ACST-2: This RCT Found That CEA And CAS For ACS Had Comparable Adverse Event Rates Up To 10 Years And Implied That Both Invasive Treatments Were Superior To Now Obsolete BMT
1:24 PM - 1:29 PM
Presenter
SESSION 93: BEST ANTIPLATELET REGIMENS UPDATE ON RARE VASCULAR DISEASES; NEW DEVELOPMENTS IN ANTIPLATELET AND ANTICOAGULATION REGIMENS AND MEDICAL AND DRUG TREATMENTS
Lowering LDL-C And Controlling Elevated Blood Pressure And Lipoprotein Little A [Lp(a)] Can Lower Cardiovascular Risk 80%: What To Do If Patients Can’t Tolerate A Statin Dose: Ezetimibe (Zetia), A PCSK9 Inhibitor, Inclisiran, Bempedoic Acid (Nexletol), Etc.
3:30 PM - 3:35 PM